Bladder cancer: haematuria recognition and the AU general practice pathway

Bladder cancer in Australian general practice

Bladder cancer is the fourth most common cancer in Australian men, with approximately 3,000 new cases each year (Australian Institute of Health and Welfare). It predominantly affects men aged 65–80 (male-to-female ratio approximately 3:1), though it occurs in younger adults when specific risk factors — particularly occupational aromatic amine exposure or schistosomiasis — are present.

The general practice role is pivotal at every stage: most bladder cancers are first identified through haematuria investigated in general practice, and long-term survivorship care — which continues for years after specialist treatment — is anchored in the general practice relationship. The five-year relative survival rate across all stages is approximately 56%; for disease confined to the bladder lining (non-muscle-invasive disease), it is around 96% (Cancer Council Australia OCP). Stage at diagnosis is the most important determinant of outlook, which is why prompt investigation matters.

The most important rule in general practice: painless visible haematuria in any adult is bladder cancer until proven otherwise — never attribute it to a urinary tract infection without urology review and cystoscopic clearance (USANZ; RACGP haematuria guidance). UTI and bladder cancer can and do coexist.

A. Core clinical — the AU general practice framework

Presentations that should trigger investigation

Visible (macroscopic) haematuria — blood visible to the eye, appearing pink, red, brown, or containing clots — is the cardinal presentation, occurring in approximately 80% of bladder cancer cases at diagnosis. Clots suggest bladder origin. Visible haematuria may be painless, intermittent, and self-limiting; none of these features make it safe to observe without investigation (USANZ; eTG).

Microscopic haematuria — detected on dipstick or urine microscopy — warrants investigation in adults aged 35 or over with risk factors (smoking, occupational exposure, recurrent urinary tract infection), and in any adult with persistent microscopic haematuria on repeat testing.

Irritative lower urinary tract symptoms — frequency, urgency, dysuria — without confirmed infection, particularly in older adults, may indicate carcinoma in situ (CIS). CIS is a flat, high-grade, non-papillary tumour that frequently mimics urinary tract infection clinically and requires a high index of suspicion.

Recurrent urinary tract infections in men, or haematuria that fails to resolve after a six-week re-check urinalysis post-antibiotic treatment, mandates further investigation regardless of culture results.

Loin pain or lower-limb oedema can indicate locally advanced disease with ureteric obstruction or vascular compression.

Risk factors to assess in history

Smoking is by far the most important modifiable risk factor. Current smokers have four to five times the bladder cancer risk of non-smokers, and approximately half of all bladder cancers in Australia are attributable to tobacco (EAU NMIBC 2024). Offering smoking cessation support at every contact is non-negotiable for any patient with bladder cancer or its risk factors.

Occupational aromatic amine exposure — in rubber manufacturing, aniline dye production, leather tanning, paint and printing industries, hairdressing, aluminium smelting, and dry cleaning — carries a 2–5-fold risk increase with a typical latency of 20–40 years. Workers’ compensation is available in most Australian states for occupationally acquired bladder cancer. Ask explicitly about past occupations.

Pelvic radiation (for prostate, gynaecological, or rectal cancer) carries a bladder cancer risk with a latency of 10–20 years. Previous cyclophosphamide chemotherapy is a recognised risk through the acrolein metabolite.

Schistosomiasis (S. haematobium) — a parasitic infection endemic in sub-Saharan Africa, Egypt, the Middle East, and parts of South America — is associated with squamous cell carcinoma of the bladder in returned travellers and refugees. Serology and specialist review are appropriate in this population presenting with haematuria.

Aristolochic acid from certain Chinese herbal preparations (sometimes labelled “Mu Tong” or similar) is a direct urothelial carcinogen. Explicit questioning about herbal medicine use is warranted.

Other risk factors include: Lynch syndrome (upper-tract urothelial more than bladder), pioglitazone (small but consistent signal; consider alternative diabetes agents in at-risk patients), and arsenic in drinking water (relevant in some rural bore-water settings).

Investigation pathway

Initial general practice investigations for visible haematuria (USANZ; eTG):

• Urinalysis and microscopy — confirm red blood cells; exclude pseudohaematuria (beeturia, rifampicin, myoglobinuria); note proteinuria and red blood cell casts
• Urine MC&S — treat any infection; crucially, recheck urinalysis at six weeks post-antibiotic treatment — persistent haematuria mandates further investigation regardless of culture results
• Urine cytology — send fresh second-morning specimen; sensitivity is low for low-grade disease (~15–40%) but high for high-grade disease and CIS (~80–95%); a negative result does not exclude bladder cancer (EAU NMIBC 2024)
• Full blood count, urea and electrolytes with eGFR, liver function tests, corrected calcium, urine albumin-to-creatinine ratio — baseline and to exclude concurrent glomerular disease

CT urogram (MBS item 56507 — CT abdomen and pelvis with contrast plus excretory/delayed phase) is first-line imaging for visible haematuria in Australian adults (USANZ). It visualises the kidneys, ureters, and bladder, identifying filling defects and upper tract lesions. CT urogram should not be replaced by renal tract ultrasound — ultrasound alone is insufficient to exclude bladder cancer and should not be used as the sole imaging modality.

Urology referral for visible haematuria should occur within two weeks, concurrent with CT urogram. Flexible cystoscopy (MBS item 36812) is the gold standard for bladder mucosal assessment — an outpatient procedure under local anaesthetic. If a tumour is identified, it proceeds to TURBT (transurethral resection of bladder tumour) under general anaesthetic, which is simultaneously the definitive diagnostic procedure and the primary treatment for non-muscle-invasive disease (MBS item 36815).

B. Staging, non-muscle-invasive disease, and the evidence base

Staging

Bladder cancer is staged by depth of invasion using the TNM system. The critical clinical distinction is non-muscle-invasive bladder cancer (NMIBC) — comprising Ta (non-invasive papillary), Tis (carcinoma in situ, flat and high-grade), and T1 (invasion into the lamina propria but not the muscularis propria) — versus muscle-invasive bladder cancer (MIBC) — T2 and beyond.

At diagnosis, approximately 75% of bladder cancers are NMIBC (EAU NMIBC 2024). However, 40–70% of NMIBC recurs within five years, driving the structured long-term cystoscopic surveillance burden that patients carry for years after initial treatment.

NMIBC treatment — TURBT plus intravesical therapy

After TURBT, risk stratification guides the intensity of intravesical therapy:

• Low-risk disease (single small low-grade Ta, first occurrence) — a single immediate intravesical mitomycin instillation within six hours of TURBT, followed by cystoscopic surveillance at 3 months, 9 months, then annually for 5 years. The Sylvester EORTC meta-analysis demonstrated a 12% absolute reduction in five-year recurrence.
• Intermediate-risk disease — intravesical mitomycin or epirubicin induction (6 weekly instillations) with or without maintenance; or BCG induction plus one-year maintenance.
• High-risk disease (any T1, any high-grade, any CIS, recurrent intermediate-risk) — intravesical BCG induction (6 weekly instillations) plus maintenance (3-weekly instillations at 3, 6, and 12 months, continuing for up to 3 years) is the standard of care (Sylvester EORTC). BCG is a PBS Section 100 Highly Specialised Drug, hospital-supplied; global supply has periodically been constrained.
• BCG-unresponsive disease — early radical cystectomy is the standard; pembrolizumab immunotherapy for BCG-unresponsive CIS is an emerging option (KEYNOTE-057 — verify current PBS authority).

High-grade T1 tumours and cases where TURBT histology does not include muscularis propria tissue warrant re-TURBT at 2–6 weeks — up-staging occurs in 10–25% of these cases, significantly altering management.

MIBC treatment

Muscle-invasive bladder cancer requires multimodal specialist management via an oncology MDT (EAU MIBC 2024):

• Neoadjuvant cisplatin-based chemotherapy — gemcitabine plus cisplatin, or dose-dense MVAC, before radical cystectomy. The SWOG-8710 trial (Grossman NEJM 2003) demonstrated a five-year absolute survival benefit of approximately 5%, with pathological complete response in 38% versus 15% with surgery alone. Routine if cisplatin-fit (eGFR ≥60, ECOG 0–1, no significant comorbidities).
• Radical cystectomy with pelvic lymphadenectomy and urinary diversion (MBS item 36848) — ileal conduit (most common), orthotopic neobladder (selected patients), or continent cutaneous diversion.
• Adjuvant nivolumab for high-risk pathology (pT3 or above, node positive, or ypT2 or above after neoadjuvant therapy) — the CheckMate 274 trial (Bajorin NEJM 2021) demonstrated disease-free survival benefit (HR 0.70). PBS Section 100 EFC listed.
• Bladder-preserving trimodal therapy — maximal TURBT plus concurrent chemoradiation — for selected patients (small unifocal T2 tumour, no CIS, no hydronephrosis, patient preference or surgical unfitness). Long-term survival is comparable in observational cohorts but no prospective head-to-head RCT has been completed; this is an MDT decision.

C. Systemic therapy for metastatic disease

The treatment of metastatic urothelial carcinoma has been substantially changed by the emergence of immunotherapy and antibody-drug conjugates.

Enfortumab vedotin plus pembrolizumab has become the new first-line standard regardless of cisplatin eligibility, following the EV-302/KEYNOTE-A39 trial (Powles NEJM 2024), which demonstrated median overall survival of 31.5 months versus 16.1 months, and objective response rate of 68% versus 44%, compared with platinum-based chemotherapy. This combination received PBS Section 100 EFC listing in late 2025/early 2026 — verify current authority criteria and start dates with the PBS as eligibility requirements evolve.

For patients not on the enfortumab vedotin plus pembrolizumab pathway, gemcitabine plus cisplatin (or dose-dense MVAC) followed by maintenance avelumab for patients with non-progressive disease after platinum chemotherapy remains an alternative first-line approach — the JAVELIN Bladder-100 trial (Powles NEJM 2020) showed median overall survival of 21.4 versus 14.3 months. PBS Section 100 EFC listed.

Pembrolizumab monotherapy is available for cisplatin-ineligible, PD-L1-positive patients when the enfortumab vedotin combination is not accessible — based on the KEYNOTE-052 trial (Balar Lancet Oncol 2017).

Second-line options after platinum chemotherapy include pembrolizumab, enfortumab vedotin monotherapy, and erdafitinib for FGFR2/3-altered tumours.

D. Australian operations

Medicare items supporting general practice management of bladder cancer (MBS Online):

• GP consultations — items 23/36/44
• GP Chronic Condition Management Plan (GPCCMP) — items 965/967 for coordinating long-term survivorship care, post-cystectomy monitoring, comorbid chronic kidney disease, and smoking cessation
• Allied health under GPCCMP — dietitian and exercise physiologist items 10953/10954; stomal therapy nursing for ileal conduit care
• Mental Health Treatment Plan — items 2715/2717 for psychological distress; psychology items 80000–80020; depression prevalence is approximately 30% post-cystectomy
• Health assessments — Aboriginal and Torres Strait Islander item 715; 75+ item 705; refugee item 707
• Multidisciplinary case conferencing — items 735/739/743/747
• Pathology — FBC 65070, UEC 66500, urine cytology 73055 range, MSU 69300, B12 and iron studies post-diversion, urine ACR 66536

PBS medicines relevant to general practice in bladder cancer care:

• Smoking cessation — nicotine replacement therapy (general schedule), varenicline and bupropion (Authority); see RACGP smoking cessation guidance
• Vitamin B12 — replacement post-ileal conduit or neobladder (ileal segment B12 malabsorption)
• Systemic anticancer agents — BCG, mitomycin, nivolumab, pembrolizumab, enfortumab vedotin plus pembrolizumab — are Section 100 HSD or EFC, specialist-initiated and hospital-supplied; verify authority criteria at PBS

Medico-legal considerations (Cancer Council Australia OCP):

• Attributing visible haematuria to UTI without cystoscopic clearance is a recurrent source of medico-legal claims. Document the six-week urinalysis recheck plan, the CT urogram request, and the urology referral
• Failure to take an occupational history — workers’ compensation implications for aromatic-amine-exposed patients
• Anticoagulation does not explain haematuria — investigate fully regardless of the anticoagulant indication
• Failure to consider schistosomiasis in returned travellers and refugees

DVA veterans: Vietnam veterans and those with chemical or hydrocarbon exposures in service may be eligible for DVA-accepted service-related bladder cancer pathways.

Telehealth (existing-relationship 12-month rule, MBS 91 range) is useful for surveillance review, scan result discussion, and survivorship coordination.

E. Special populations

Older adults. Most patients are diagnosed over 70. Perioperative risk assessment and comprehensive geriatric assessment are important when radical cystectomy is being considered. For patients not fit for curative intent, de-escalated options — haemostatic TURBT, intravesical therapy, palliative radiotherapy, or symptom-directed care — are appropriate. Polypharmacy review is important given the interaction potential of systemic anticancer agents.

Aboriginal and Torres Strait Islander Australians. Rates of late-stage presentation are higher, partly reflecting barriers to investigation in rural and remote settings. Proactive haematuria questioning at preventive health encounters and the item 715 health assessment can facilitate earlier investigation and referral. Explain the investigation pathway clearly; support systems for attending specialist appointments in urban centres are often needed.

Refugees and returned travellers. Schistosomiasis (S. haematobium) in patients from endemic regions — sub-Saharan Africa, Egypt, the Middle East, and parts of Brazil — causes squamous cell carcinoma of the bladder, presenting with haematuria years to decades after exposure. Request schistosomiasis serology alongside the haematuria workup and arrange infectious disease and urology review. Praziquantel eradicates active infection.

Post-cystectomy survivorship — a key ongoing general practice role:

• Vitamin B12 — the ileal segment used for conduit or neobladder construction absorbs B12, leading to deficiency over years; monitor annually and replete with intramuscular injection or high-dose oral supplementation
• Acid-base balance — hyperchloraemic metabolic acidosis occurs when urinary ammonium is reabsorbed through the bowel segment; monitor serum bicarbonate, particularly in patients with impaired kidney function
• Sexual health and pelvic floor rehabilitation — erectile dysfunction is common after radical cystectomy and cystoprostatectomy in men; vaginal stenosis and dyspareunia affect women after anterior exenteration; referral to pelvic floor physiotherapy and sexual health services is appropriate
• Psychological support — body image change from a urostomy, loss of natural bladder function, and ongoing cystoscopic surveillance contribute significantly to depression and anxiety; Cancer Council peer support (13 11 20) and Bladder Cancer Australia (BEAT-IT) are valuable resources
• Cardiovascular risk reduction — smokers and post-cystectomy patients carry high cardiovascular mortality; statins, blood pressure management, glucose control, and lifestyle review are standard

Younger adults (under 40). Bladder cancer in this age group is uncommon and warrants consideration of rare causes: aristolochic acid herbal exposure, previous cyclophosphamide, schistosomiasis, upper-tract urothelial primary with bladder seeding, or Lynch syndrome (especially with a family history of upper-tract urothelial cancer).

When to escalate

Refer urgently (within two weeks):

• Any adult with visible haematuria — concurrent urology referral and CT urogram
• Microscopic haematuria persisting after treated UTI in adults ≥35 with risk factors — urology
• Visible haematuria with confirmed bladder mass on imaging — urgent MDT referral

Emergency presentation:

• Massive haematuria with clot retention (urological emergency — catheterisation, bladder irrigation)
• Suspected urosepsis or pyelonephritis with obstructing tumour

Routine referral:

• Unexplained irritative lower urinary tract symptoms in older adults without documented infection — urology (consider CIS)
• Post-cystectomy progressive chronic kidney disease — nephrology plus GPCCMP
• Post-treatment psychological distress — MHTP and psycho-oncology referral

What this article is and is not

This is general health information drawn from the Cancer Council Australia Optimal Care Pathway for Bladder Cancer, USANZ position statements, Therapeutic Guidelines — Urology, RACGP haematuria guidance, and major international trial data (EAU 2024). It is not personal medical advice and does not create a doctor–patient relationship. Treatment decisions are made with your own GP, urologist, and the multidisciplinary oncology team.

Consumer resources: HealthDirect — Bladder cancer; Cancer Council Australia — 13 11 20; Bladder Cancer Australia — BEAT-IT; Better Health Channel — Bladder cancer.

---

Sources cited

1. Cancer Council Australia — Optimal Care Pathway for Bladder Cancer
2. USANZ — Bladder cancer position statements
3. Therapeutic Guidelines (eTG) — Urology: bladder cancer
4. RACGP — Investigation of haematuria in adults
5. EAU — Non-muscle-invasive Bladder Cancer Guideline 2024
6. EAU — Muscle-invasive and Metastatic Bladder Cancer Guideline 2024
7. Grossman HB et al. — SWOG-8710 neoadjuvant MVAC + cystectomy (NEJM 2003)
8. Sylvester RJ et al. — EORTC meta-analysis BCG vs mitomycin
9. Bajorin DF et al. — CheckMate 274 adjuvant nivolumab (NEJM 2021)
10. Powles T et al. — EV-302/KEYNOTE-A39 enfortumab vedotin + pembrolizumab (NEJM 2024)
11. Powles T et al. — JAVELIN Bladder-100 maintenance avelumab (NEJM 2020)
12. Balar AV et al. — KEYNOTE-052 pembrolizumab 1L cisplatin-ineligible (Lancet Oncol 2017)
13. MBS Online — items 23, 36, 44, 91, 705, 707, 715, 735–747, 965, 967, 2715, 2717, 10953, 10954, 36812, 36815, 36848, 56507, 65070, 66500, 66536, 69300, 73055, 80000–80020
14. PBS — BCG, mitomycin, nivolumab, pembrolizumab, EV + pembrolizumab, avelumab, smoking cessation pharmacotherapy
15. HealthDirect — Bladder cancer; Cancer Council Australia; Bladder Cancer Australia — BEAT-IT